Correlation of CD44 Protein Expression with Larger Tumor Size and Advanced Stage of Breast Cancer Patients Authors: Desak Made Wihandani, Ida Ayu Dewi Wiryanthini, Made Violin Weda Yani, Ni Putu Sri Indrani Remitha, I Gusti Ayu Stiti Sadvika, Anak Agung Bagus Putra Indrakusuma, Putu Anda Tusta Adiputra, I Gede Putu Supadmanaba Published: 2024 ABSTRACT AbstractObjectives:This study aimed to determine the expression of CD44 in breast cancer and its association with patients’ clinicopathological data, particularly in Bali.Material and Methods:This was a cross-sectional study in the Integrated Biomedical Laboratory and Biochemistry Laboratory of the Faculty of Medicine Udayana University, during January-December 2022, which lasted 12 months with 46 samples. Results:The study showed that the age range of our subjects was 38-86 years old, with the majority of the parity being less than three. The mean CD44 expression in all samples was 1177.83 ± 268.47 ng/mL. Based on the clinicopathological data, there was a significant difference in CD44 expression based on the patient’s menstrual status (p=0.016), tumor size (p=0.003), and stage (p=0.002). Based on the analysis using the chi-square test with a cut-off CD44 expression of 85.81, significant results (p=0.001) were obtained on the association of CD44 expression with tumor size. The cut-off value with the stage of breast cancer was 99.66 and showed a significant association between CD44 expression advanced stage (p = 0.001) in breast cancer patients. Other variables showed insignificant results. Conclusion: CD44 protein expression in breast cancer patients is between 35.47-1407.83 ng/mL. This study showed a significant association between CD44 expression with tumor size and the advanced stage of breast cancer patients. Key Words: Bali, Breast Cancer, CD44, Clinicopathology Introduction Breast cancer is one of the leading causes of cancer worldwide. According to the American Cancer Society, breast cancer is the second leading cause of cancer mortality in female patients after lung cancer. In addition, with an average risk of 12%, this cancer may affect one in eight women in America. In 2017, it was projected that there would be around 40,610 cancer-related deaths, 252,710 invasive cases, and 63,410 non-invasive (CIS) cases diagnosed [1]. According to the World Health Organization (WHO) 2018, the mortality rate of breast cancer is 627,000, or approximately 15% of deaths of all types of cancers that affect women. In the Asia Pacific, Indonesia reaches third place with the highest prevalence of breast cancer (12%) after China (46%) and Japan (14%). The prevalence of breast cancer in Indonesia is 41.7%, with a mortality rate is 22% [2]. Breast cancer is a highly complex and heterogeneous disease that has diverse clinical and biological behaviors. It also has distinct responses to any treatment that can be classified into certain subtypes according to histopathological types and molecular profiles [3]. Tumor heterogeneity in breast carcinoma is related to the presence of populations of heterogeneous cells within a single patient (intratumor heterogeneity) or between different patients (inter-tumor heterogeneity), resulting in the clinical manifestations of the disease. Although the understanding of breast cancer heterogeneity has increased significantly, there are still several obstacles standing in the way of reaching a better diagnosis, treatment, and prognosis of breast cancer disease [4]. CD44 is a complex transmembrane adhesion glycoprotein found in several molecular forms, such as the standard and variant isoforms. CD44 is a molecule that is specifically located on chromosome 11p13. Hyaluronic acids and the main components of the extracellular matrix are intrinsically linked to CD44. Moreover, CD44 can interact with other cell surface receptors to facilitate the activation of distinct signaling pathways that control cell migration, survival, cell invasion, and the epithelial-mesenchymal transition (EMT). CD44 has also been revealed to play a role in cellular signaling and cell-cell communication by creating complexes between extracellular components and intracellular cytoskeletal elements. In addition, CD44 regulates various cell behaviors, such as cell survival, proliferation, differentiation, and motility, and it has been linked to sensing changes in the extracellular matrix and the cellular microenvironment. Moreover, the previous study also stated that the expression of CD44 correlated with tumor grade and recurrence in breast cancer patients. It is also reported that CD44 may promote cancer metastasis [4]. The evidence of CD44 genes related to clinicopathological aspects in breast cancer was shown in some previous studies. The CD44 expression was found to correlate with HER-2 negative patients [5]. In addition, increased CD44 expression is associated with tumor grade and distant metastasis [6]. However, in a previous study, it was found that there was no correlation was found between CD44-positive / CD24-negative with the size of the tumor, nodal status, and metastasis, but it was related to the overall stage [7]. With these variable findings, there is a need to conduct a study associated with CD44 expression as well as its association with clinicopathological aspects of breast cancer. The studies conducted in Indonesia are scarce and need to be evaluated considering the diversity of ethnicities and demographics of the country. Our present study takes place in Bali, considering the scarcity of the study that is related to the topic and the increasing number of breast cancers from time to time. Therefore, it is necessary to investigate the CD44 expression and its association with clinicopathological aspects of breast cancer patients in Bali. This study was expected to encourage further breast cancer research to support patients’ prognoses Materials and Methods Study design This study was conducted using a cross-sectional study in the Integrated Biomedical Laboratory and Biochemistry Laboratory of the Faculty of Medicine Udayana University, during January-December 2022. Eligibility Criteria of Participants A consecutive sampling technique was used as a sampling method in this study with 46 patients who met the criteria to be the subject of this study. In this study, the inclusion criteria were (1) patients diagnosed with breast cancer who underwent a complete blood count in the clinical pathology laboratory of Prof. dr. IGNG Ngoerah General Hospital, (2) had complete medical record data, and (3) willing to participate in the study through informed consent. Exclusion criteria were (1) pregnant women and nursing mothers, (2) patients with a history of other malignancies, (3) patients with impaired liver or kidney function, and (4) taking multivitamins. Blood Sampling A peripheral blood sample (5 ml) was collected from the brachial vein of the patient. It was taken during a routine blood examination at Prof. dr. IGNG Ngoerah General Hospital Clinical Pathology Laboratory. The blood tube was stored in a cool box and transposed to the Faculty of Medicine’s biochemical laboratory, Universitas Udayana. As soon as the blood was collected, serum was prepared by centrifugation at 4000×g for 10 min at 4°C. The resulting supernatant was stored in an Eppendorf tube at -80 °C before the immunoassay. ELISA Procedure ELISA procedure began with preparing a sample in blood serum and reagent preparation. This procedure used the Human CD44 ELISA KIT from the Bioassay Technology Laboratory per the manufacturer’s protocol (Korain Biotech, China). The expression of CD44 protein was measured in only one group (patients with breast cancer) without subject control. In each well plate, 50 µl of standard solution was added into the standard wells, as well as 40 µl of serum in the sample wells and 10 µl of anti-CD44 antibody to each well. 50 µl of streptavidin-HRP was added to the sample and standard wells. The mixtures were homogenated, covered with a sealer cover, and incubated at 37oC for 60 minutes. 50 µl of substrate solution-A and 50 µl of substrate solution-B were then added to all wells. The plate was then covered with a sealer cover and incubated at 37oC for 10 minutes in a dark room. Subsequently, 50 µl of stop solution was added to each well, and the color was expected to change from blue to yellow immediately. The ELISA plate was then read by using a microplate reader at 450 nm. Statistical analysis All numerical data in this study, including CD44 expression, were analyzed using the Shapiro-Wilk normality test. As the result showed that the data was not normally distributed, this study used a non-parametric test (Mann-Whitney). All nominal data were analyzed using the Chi-square test. The p-value <0.05 was considered significant. All analysis tests used SPSS software for Windows version 25.0 Results This study’s youngest and oldest ages were 38 years and 86 years, respectively, with a mean age of 54.24 years. Based on parity, the result of this analysis was obtained with the majority <3 Children (87.0%). Also, 56.5% of breast cancer patients were postmenopausal, and 43.5% were premenopausal. In clinicopathological aspects of breast cancer patients in Prof. dr. IGNG Ngoerah General Hospital, it was found that most of the patients (78.3%) had a tumor size ≥ 5 cm, 47.8% with N1 regional lymph node metastases, and 65.2% of patients without distant metastases (M0). The patients’ primary tumor was equal, with 50% in dextra mammae and 50% in sinistra mammae. Based on Karnofsky’s score, 87% of the patients had scores ≥90%, and the rest (13%) with <90%. In this study, the breast cancer stage was divided into four groups, with most of the patients had stage III (45.7%) and stage IV (34.8%). The histopathological grade was divided into three groups: 43.5% of the patients were in grade III, 37% were in grade II, and the rest were in grade I. The estrogen receptor (ER), progesterone receptor (PR), and HER2 status of breast cancer patients in this study were divided into two groups, which are positive and negative. Most breast cancer patients have positive ER status (65.2%). Meanwhile, the patients’ PR status was equal in the positive (50%) and negative (50%) groups. At HER2 status, 52.2% of patients were HER2 positive. About 80.4% of patients had high Ki67, and 19.6% had low Ki67. Based on histological subtypes, 30.4% of patients with luminal-B were followed by luminal-A and HER2 subtypes with 19.6% each, then luminal- HER2 and Triple Negative Breast Cancer (TNBC) subtypes were 17.4% and 13%, respectively. CD44 ELISA results showed that the mean CD44 expression of all breast cancer patients was 177.83±268.47 ng/mL, with a median expression of 81.42 ng/mL. The lowest value of CD44 expression was 35.47 ng/mL. Meanwhile, the highest value was 1407.83 ng/mL, as seen in Table 1. Table 1Characteristics of Breast Cancer PatientsCharacteristicNumber of Samples (n=46)Frequency (n)Percentage (%)Age Mean (Years Old) 54.24±10.67 Minimum 38 Maximum86Parity < 3 (low parity)4087.0 ≥ 3 (high parity)613.0Menstrual status Pre-menopause2043.5 Post-menopause2656.5Tumor Size <5 cm1021.7 ≥ 5 cm3678.3Lymph Node Metastasis N01430.4 N12247.8 N2715.2 N336.5Distant Metastasis M03065.2 M11532.6Primary Tumor Location Dextra2350.0 Sinistra2350.0Karnofsky Score < 90%613.0 ≥ 90%4087.0Stage I36.5 II613.0 III2145.7 IV1634.8Histopathological Grade Grade 1919.6 Grade 21737.0 Grade 32043.5ER status Negative16 Positive30PR status Negative23 Positive23HER-2 status Negative 22 Positive24Ki67 Low919.6 High3780.4Histopathological Subtype Luminal A919.6 Luminal B1430.4 Her2919.6 TNBC613.0 Luminal-HER2817.4CD44 Mean±SD177.83±268.47 Median81.42 Range (Min-Max)35.47-1407.83 Characteristics of Breast Cancer Patients Based on the mean difference test in Table 2, there was a significant difference in CD44 expression based on the patient’s menstrual status, tumor size, and stage. We continued the analysis using ROC curve analysis to find the cut-off value of CD44. The cut-off value of CD44 in tumor size was 85.81 (Table 3; Figure 1). The other fact, the cut-off value of CD44 in the tumor stage was 99.66 (Table 4; Figure 2). Table 2Association of CD44 Expression with the Clinicopathological Aspect of Breast Cancer PatientsCD44 Expression Mean diff (CI95%) P-valueAge <52 years old158.07 (12.79-303.35)0.078 ≥ 52 years oldParity < 3 (low parity)81.27 ((-157)-319.55)0.636 ≥ 3 (high parity)Menstrual Status Pre-Menopause67.04 ((-311.03) – (-35.25))0.016* Post-MenopauseTumor Size <5 cm91.72 (25.58-395.28)0.003* ≥ 5 cmLymph Node Metastasis Without metastasis174.10 ((-78.08)-426.29)0.17 With metastasisDistant Metastasis Without metastasis30.33 ((-163.63)-224.31)0.068 With metastasisPrimary Tumor Location Dextra21.43 (139.79-182.94)0.606 SinistraKarnofsky Score < 90%124.61 (111.93-361.15)0.234 ≥ 90%Stage Early (I-II)239.778 (49.90-429.655)0.002* Advance (III-IV)Histopathological Grade Grade I-II130.61 (11.43-272.67)0.352 Grade IIIHistopathological Subtype Luminal 83.51 (-86.70-253.73)0.87 Non-LuminalER Status Negative36.96 ((-132.05)-205.98)0.721 PositivePR Status Negative9.85 ((-171.18)-151.47)0.435 PositiveHER-2 Negative6.90 ((-154.58)-168.40)0.218 PositiveKi-67 Low87.12 ((-288.76)-114.52)0.198 High Association of CD44 Expression with the Clinicopathological Aspect of Breast Cancer Patients Table 3The AUC, Cut-off Value, Sensitivity, and Specificity for CD44 for Tumor Size of Breast CancerParameterAUC95%CICut-off valueSensitivitySpecificityp-value CD44 0.8140.66-0.9685.8190%66.70%0.003**significant (p<0.05) The AUC, Cut-off Value, Sensitivity, and Specificity for CD44 for Tumor Size of Breast Cancer *significant (p<0.05) The ROC Curve Analysis of CD44 for Tumor Size Table 4The AUC, Cut-off Value, Sensitivity, and Specificity for CD44 for Cancer-StageParameterAUC95%CICut-off valueSensitivitySpecificityp-value CD44 0.8380.68-0.9999.6688.90%73%0.002**significant (p<0.05) The AUC, Cut-off Value, Sensitivity, and Specificity for CD44 for Cancer-Stage *significant (p<0.05) The ROC Curve Analysis of CD44 based on the Stage of Breast Cancer Based on the cut-off value CD44 expression (85.81 ng/ml; obtained from ROC analysis), we classified the group into “high” and “low” categories. Analyzing the association between these categories with tumor size revealed that CD44 expression was significantly associated with tumor size with Odds Ratio (OR) 18.0 (p=0.001) (Table 5) which indicate higher risk of having larger tumor in breast cancer patients with high CD44 expression. Using similar method, we classify the group into “high” and “low”, then analyzed its association with tumor stage (Early vs. Advanced). Accordingly, we also found significant association between CD44 expression to tumor stage (OR: 21.6 (p:0.001*)) with higher CD44 expression has higher risk of having advanced tumor (Table 6). Meanwhile, other variables did not show significant results. Table 5The Chi-Square Analysis of the Association between CD44 with Tumor SizeVariableStage of tumorOR (p-value)AdvanceEarly CD44 High (≥99.66 ng/ml)27 (96.4)1 (3.6)21.6 (0.001*) Low (<99.66 ng/ml)10 (55.6)8 (44.4) The Chi-Square Analysis of the Association between CD44 with Tumor Size Table 6The Chi-Square Analysis of the association between CD44 with StageVariableTumor sizeOR(p-value)≥5 cm<5 cm CD44 High (≥85.81 ng/ml)24 (96.0)1 (4.0)18.0 (0.001*) Low (<85.81ng/ml)12 (57.1)9 (42.9) The Chi-Square Analysis of the association between CD44 with Stage Discussion This study is one of the few studies that rarely addresses CD44 plasma serum in breast cancer. Several other studies that have been published mostly used stem cells and tissues. CD44 is a non-kinase transmembrane glycoprotein expressed on embryonic stem cells and various cell types, including connective tissue and bone marrow [8]. This study showed a proportion difference in CD44 expression with the patient’s age. More severe disease phenotypes are frequently correlated with CD44 expression. Both younger and older individuals have increased CD44 expression; however, other research suggests that age may not be a relevant factor in CD44 expression levels. On the other hand, advanced tumor stages may have higher CD44 expression, which may be associated with older age groups [9]. There was a significant relationship between CD44 expression and menstrual status. Based on menstrual status, menopause is the last menstrual cycle experienced by a woman with clinical manifestations of menstruation cessation. This study found a significant difference in the proportion of CD44 expression between the premenopausal and postmenopausal groups. CD44 is expressed mainly in endometrial stromal cells during the secretion phase. Meanwhile, glandular epithelial cells do not express CD44. Expression of CD44 during the secretion phase indicates that the molecule was involved in implanting a fertilized ovum. CD44 also functions in the early stage of the adhesive contact between the endometrium and ovum. Thus, the absence or decrease of CD44 expression in the endometrium in this phase may cause infertility or early abortion [10]. This study showed a significant relationship between CD44 expression and tumor size but not significant with regional lymph node metastasis and distant metastasis. Higher CD44 expression was associated with tumor size [11]. CD44 plays a crucial part in tumor development, invasion, and metastasis. Research indicates that higher levels of CD44 expression are linked to more extensive tumors because CD44 enhances the characteristics of cancer stem cells (CSCs) that facilitate tumor development, invasion, and metastasis. Through improving survival pathways, CD44-positive CSCs in breast cancer encourage cell proliferation and tumor growth [9, 12]. This study also found a significant association between CD44 and the stage of breast cancer. Studies show that CD44 is clinically correlated with the stage of breast cancers, implying that higher levels of CD44 are frequently associated with more aggressive tumors with a higher potential for metastasis, especially in patients with triple-negative breast cancer (TNBC); in other words, higher levels of CD44 expression are linked to later stages of breast cancer [3]. Compared to previous stages (I and II), stage III and IV cancers frequently have higher levels of CD44, which may indicate a function for CD44 in the metastasis and development of the tumor [12]. There was no significant relationship between CD44 expression and breast cancer patients’ ER, PR, and HER2 status. Breast cancer with ER+ has the best prognosis, with a low incidence rate in the first five years. In contrast, TNBC breast cancer showed the worst prognosis, and nearly all metastases occur within the first five years, with the incidence rate increasing in the first one or two years [13]. However, this study showed no significant association between CD44 expression with primary tumor and metastatic location. This study showed the difference between the proportion of CD44 expression between the Ki67 group was 20.8% but no significant correlation. This result is similar to that conducted by Farida, [14], which used 44 samples of breast cancer patients at Dr. Moh. Hoesin Palembang Hospital [14]. The functional status of patients was assessed on an 11-point scale ranging from all points filled up completely (100%) until cancer patients died (0%) [15]. It was found that there was no significant relationship between CD44 expression and Karnofsky score in breast cancer patients. Despite our findings, there are some limitations in this study. This study uses a small sample size, therefore, further studies with a larger sample are needed to represent more representative results. Additional research is required in order to evaluate the more specific CD44 variant and its relation to the clinicopathological condition and prognosis of breast cancer patients. In conclusion, based on the study results, it can be concluded that the CD44 protein expression in breast cancer patients is between 35.47 and 1407.83 ng/mL. This study showed a significant relationship between CD44 expression with tumor size and the stage of breast cancer patients. Therefore, CD44 expression may be beneficial to predict the prognosis of breast cancer patients. Author Contribution Statement All authors contributed to the research processes, including data analysis, drafting, and revising the paper. The authors gave final approval of the published version of the study. Acknowledgements Funding Statement A grant from Udayana University supported this study. Ethical Declaration The Research Ethics Committee of Udayana University approved this study. Letter of Exemption Number 1483/UN.14.2.2/VII.14/LT/2020. Data Availability The corresponding author will provide the datasets used and/or analyzed during the current work upon reasonable request. Conflict of Interest All authors declare there was no conflict of interest regarding this study. References Associated Data Data Availability Statement The corresponding author will provide the datasets used and/or analyzed during the current work upon reasonable request.